Lipopolysaccharide Adsorption (Efferon LPS) in Patients With Ulcerative Colitis and Crohn Disease

Inclusion Criteria: * Crohn's disease (ICD-10: K50), extensive disease, with a chronic continuous or relapsing course during an exacerbation (flare), including: * Severe flare: CDAI ≥ 450 and/or SES-CD \> 15; * Moderate flare: CDAI 350-450 and/or SES-CD \> 7, steroid-refractory. * Ulcerative colitis (ICD-10: K51), with a chronic continuous or relapsing course during an exacerbation (flare), including: * Severe flare: Mayo score ≥ 10 and partial Mayo score ≥ 6; * Moderate flare: Mayo score 6-9 and partial Mayo score ≥ 3, steroid-refractory or steroid-dependent. * Presence of signs and symptoms of ulcerative colitis or Crohn's disease for at least 3 months prior to study enrollment. * The diagnosis must be confirmed by clinical and endoscopic findings and supported by a histopathology report * The patient's condition allows Efferon LPS therapy to be performed for at least 2 hours Exclusion Criteria: * Indeterminate colitis, radiation colitis, ischemic colitis,confirmed presence of megacolon, strictures, or stenosis causing symptoms of intestinal obstruction. * Expected need for bowel resection within 4 weeks after enrollment * Presence at hospitalization of a stoma, ileal pouch-anal anastomosis, or a fistula with purulent discharge (which, in the investigator's opinion, is likely to require surgical or medical intervention within 4 weeks after enrollment), or planned ileostomy or colostomy. * Partial or total colectomy, small bowel resection, or creation of a stoma…